JP2014525429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525429A5 JP2014525429A5 JP2014527686A JP2014527686A JP2014525429A5 JP 2014525429 A5 JP2014525429 A5 JP 2014525429A5 JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014525429 A5 JP2014525429 A5 JP 2014525429A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- aureus
- polypeptide
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 63
- 239000000427 antigen Substances 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical class 0.000 claims description 24
- 229910052751 metal Inorganic materials 0.000 claims description 22
- 239000002184 metal Substances 0.000 claims description 22
- 230000002163 immunogen Effects 0.000 claims description 20
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 11
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 108010006464 Hemolysin Proteins Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 239000003228 hemolysin Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims 5
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 claims 3
- 229940125904 compound 1 Drugs 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000000556 agonist Substances 0.000 description 25
- 102000002689 Toll-like receptor Human genes 0.000 description 23
- 108020000411 Toll-like receptor Proteins 0.000 description 23
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000045715 human TLR7 Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530162P | 2011-09-01 | 2011-09-01 | |
| US61/530,162 | 2011-09-01 | ||
| US201261607999P | 2012-03-07 | 2012-03-07 | |
| US61/607,999 | 2012-03-07 | ||
| PCT/EP2012/067032 WO2013030378A1 (en) | 2011-09-01 | 2012-08-31 | Adjuvanted formulations of staphylococcus aureus antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525429A JP2014525429A (ja) | 2014-09-29 |
| JP2014525429A5 true JP2014525429A5 (enExample) | 2015-10-01 |
Family
ID=46763095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527686A Pending JP2014525429A (ja) | 2011-09-01 | 2012-08-31 | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140363461A1 (enExample) |
| EP (1) | EP2763695A1 (enExample) |
| JP (1) | JP2014525429A (enExample) |
| KR (1) | KR20140066212A (enExample) |
| CN (1) | CN104093418A (enExample) |
| AU (1) | AU2012300765A1 (enExample) |
| BR (1) | BR112014004782A2 (enExample) |
| CA (1) | CA2847204A1 (enExample) |
| IL (1) | IL231104A0 (enExample) |
| IN (1) | IN2014CN02152A (enExample) |
| MX (1) | MX2014002363A (enExample) |
| RU (1) | RU2014112343A (enExample) |
| SG (1) | SG11201400210RA (enExample) |
| WO (1) | WO2013030378A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2523732T5 (es) * | 2009-04-03 | 2023-10-23 | Momenta Pharmaceuticals Inc | Control de composiciones de copolímeros |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| KR20140066212A (ko) * | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
| HRP20161354T1 (hr) * | 2012-03-07 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Argininske soli agonista tlr7 |
| US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
| CN104619336A (zh) * | 2012-08-31 | 2015-05-13 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质 |
| US20150191513A1 (en) * | 2012-08-31 | 2015-07-09 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| EP2890387A1 (en) * | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilised proteins for immunising against staphylococcus aureus |
| BE1022359B1 (fr) * | 2014-03-17 | 2016-03-25 | Glaxosmithkline Biologicals Sa | Immunisation contre des infections staphylococciques des os et des articulations |
| EP3122378B1 (en) | 2014-03-26 | 2019-12-11 | GlaxoSmithKline Biologicals S.A. | Mutant staphylococcal antigens |
| WO2015144691A1 (en) * | 2014-03-26 | 2015-10-01 | Glaxosmithkline Biologicals Sa | Compositions for immunising against staphylococcus aureus |
| CN105646681B (zh) * | 2016-01-21 | 2021-07-16 | 浙江海隆生物科技有限公司 | 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用 |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| US20060188515A1 (en) | 2003-07-24 | 2006-08-24 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| NZ544542A (en) | 2003-07-24 | 2009-01-31 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| CA2555342A1 (en) | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP1939201A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| EP1939198A4 (en) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| WO2007034916A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| AU2007216247A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
| AU2007259415B2 (en) | 2006-06-12 | 2013-09-26 | Glaxosmithkline Biologicals Sa | Use of alpha-toxin for treating and preventing Staphylococcus infections |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
| ES2359123T3 (es) | 2007-08-03 | 2011-05-18 | Pfizer Limited | Imidazopiridinonas. |
| CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| PL2268618T3 (pl) | 2008-03-03 | 2015-11-30 | Novartis Ag | Związki i kompozycje jako modulatory aktywności receptorów TLR |
| CN103396415B (zh) | 2008-03-24 | 2016-08-10 | 4Sc股份有限公司 | 新的取代的咪唑并喹啉化合物 |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| CA2758490C (en) * | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| SI2445522T1 (sl) * | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
| AU2010272505B2 (en) | 2009-07-16 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Treatment of infections |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) * | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JP5848748B2 (ja) | 2010-03-23 | 2016-01-27 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物 |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US20140112950A1 (en) * | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| KR20140066212A (ko) * | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
| JP2015510872A (ja) * | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| US20150125486A1 (en) * | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
| US9375471B2 (en) * | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
| US20150191513A1 (en) * | 2012-08-31 | 2015-07-09 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| CN104619336A (zh) * | 2012-08-31 | 2015-05-13 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质 |
| EP2890387A1 (en) * | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilised proteins for immunising against staphylococcus aureus |
| JP2015528456A (ja) * | 2012-08-31 | 2015-09-28 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質 |
| RU2015106930A (ru) * | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
| GB201219420D0 (en) * | 2012-10-29 | 2012-12-12 | Novartis Ag | Staphyloccal immunogens |
| TR201807340T4 (tr) * | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
| BE1022359B1 (fr) * | 2014-03-17 | 2016-03-25 | Glaxosmithkline Biologicals Sa | Immunisation contre des infections staphylococciques des os et des articulations |
| WO2015144691A1 (en) * | 2014-03-26 | 2015-10-01 | Glaxosmithkline Biologicals Sa | Compositions for immunising against staphylococcus aureus |
| EP3122378B1 (en) * | 2014-03-26 | 2019-12-11 | GlaxoSmithKline Biologicals S.A. | Mutant staphylococcal antigens |
-
2012
- 2012-08-31 KR KR1020147008622A patent/KR20140066212A/ko not_active Withdrawn
- 2012-08-31 JP JP2014527686A patent/JP2014525429A/ja active Pending
- 2012-08-31 CA CA2847204A patent/CA2847204A1/en not_active Abandoned
- 2012-08-31 IN IN2152CHN2014 patent/IN2014CN02152A/en unknown
- 2012-08-31 SG SG11201400210RA patent/SG11201400210RA/en unknown
- 2012-08-31 EP EP12753488.1A patent/EP2763695A1/en not_active Withdrawn
- 2012-08-31 CN CN201280053918.1A patent/CN104093418A/zh active Pending
- 2012-08-31 BR BR112014004782A patent/BR112014004782A2/pt not_active IP Right Cessation
- 2012-08-31 MX MX2014002363A patent/MX2014002363A/es unknown
- 2012-08-31 AU AU2012300765A patent/AU2012300765A1/en not_active Abandoned
- 2012-08-31 US US14/240,616 patent/US20140363461A1/en not_active Abandoned
- 2012-08-31 RU RU2014112343/10A patent/RU2014112343A/ru not_active Application Discontinuation
- 2012-08-31 WO PCT/EP2012/067032 patent/WO2013030378A1/en not_active Ceased
-
2014
- 2014-02-24 IL IL231104A patent/IL231104A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014525429A5 (enExample) | ||
| US11542306B2 (en) | Flagellin-based agents and uses including effective vaccination | |
| RU2014112343A (ru) | Оставы антигенов staphylococcus aureus, содержащие адъюванты | |
| JP2015509522A5 (enExample) | ||
| JP5425642B2 (ja) | 合成ｔｌｒアゴニストの結合体およびそのための使用 | |
| US10188733B2 (en) | Vaccines comprising bisphosphonate and methods of use thereof | |
| Tonnis et al. | Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars | |
| JP7778570B2 (ja) | アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法 | |
| JP2013519645A5 (enExample) | ||
| JP2013543505A5 (enExample) | ||
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| JP2014530010A5 (enExample) | ||
| CN106163551A (zh) | 单瓶疫苗制剂 | |
| JP2013501071A5 (enExample) | ||
| JPWO2020022272A5 (enExample) | ||
| JP2015511957A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| CN112839673A (zh) | 包含流感疫苗的组合物 | |
| JP2013503148A5 (enExample) | ||
| US20130011430A1 (en) | HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER | |
| US20160263214A1 (en) | Calcium fluoride compositions | |
| US20160235839A1 (en) | Calcium fluoride compositions | |
| CN118215475A (zh) | 包含sting激动剂的佐剂组合物 | |
| JP2012506412A (ja) | 定方向性増殖および成熟のための免疫処置プロトコル |